About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT05768269

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements...

Lead sponsor: Century Therapeutics, Inc.•7 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Century Therapeutics Clinical Team

CONTACT

8885067670 [email protected]

Sponsors

Lead Sponsor

Century Therapeutics, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participant has provided written informed consent prior to any long-term follow-up (LTFU) study-specific procedures.
•Participants received at least one treatment with a cellular therapy product in an eligible index trial.
•Participant was withdrawn, early discontinued or completed an eligible index trial.
•Participant is willing and able to comply with scheduled visits, study plan, and other study procedures.

Related studies

RECRUITINGPhase 2

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

NCT05537896 · Hematological Malignancy, Neutropenia

Membrane Target Detection for Leukemia Treatment

NCT04841447 · Hematological Malignancy

A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy

NCT06106360 · Solid Tumor, Hematological Malignancy

Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

NCT02534649 · Solid Tumor, Hematological Malignancy

RECRUITINGPhase 2

Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

NCT06584006 · Hematological Malignancy, Lymphocytopenia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 25, 2025Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment375

Start dateApr 2024

Last updatedJun 25, 2025

Condition

Hematological Malignancy Solid Tumor Malignancy

Locations shown

Banner MD Anderson Cancer Center

Gilbert, Arizona

University of Southern California - Norris Comprehensive Cancer Center

Los Angeles, California

University of Maryland Medical Center

Baltimore, Maryland

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 25, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions